NCT00240916View on ClinicalTrials.gov

Ontogeny of Measles Immunity in Infants

CompletedOBSERVATIONAL
Enrollment

750

Participants

Timeline

Start Date

July 31, 1993

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2013

Conditions
Measles
Interventions
BIOLOGICAL

Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)

BIOLOGICAL

MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)

Trial Locations (2)

94301

Palo Alto Medical Foundation/Department of Pediatrics, Palo Alto

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER